OUR SCIENCE
Current immunotherapy approaches target the minority of tumours that are visible to the immune system. By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the neoantigen repertoire in cancer, increasing tumour visibility and extending the therapeutic benefit of immunotherapy to many more cancer patients.
Find out more >PROUDLY AWARDED